[Advances in CAR- T therapy for patients with multiple myeloma].
作者信息
Wu X F, Wang Y D, Hu Y
机构信息
Department of Hematology, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):921-925. doi: 10.3760/cma.j.issn.0253-2727.2016.10.023.
Abstract
摘要
相似文献
1
[Advances in CAR- T therapy for patients with multiple myeloma].[多发性骨髓瘤患者的嵌合抗原受体T细胞疗法进展]
Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):921-925. doi: 10.3760/cma.j.issn.0253-2727.2016.10.023.
2
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
3
[Clinical development of CAR-T therapy for refractory multiple myeloma].[嵌合抗原受体T细胞疗法治疗难治性多发性骨髓瘤的临床进展]
Rinsho Ketsueki. 2018;59(8):1058-1065. doi: 10.11406/rinketsu.59.1058.
4
CARs in the Lead Against Multiple Myeloma.嵌合抗原受体在对抗多发性骨髓瘤中领先。
Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2.
5
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.抗 BCMA CAR-T 细胞治疗浆细胞异常：POEMS 综合征和多发性骨髓瘤病例报告。
J Hematol Oncol. 2018 Oct 22;11(1):128. doi: 10.1186/s13045-018-0672-7.
6
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.一项针对复发或难治性多发性骨髓瘤患者的靶向 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法 LCAR-B38M 的 1 期、开放性研究。
J Hematol Oncol. 2018 Dec 20;11(1):141. doi: 10.1186/s13045-018-0681-6.
7
[New Research Advances on Chimeric Antigen Receptor T Cells in the Treatment of Relapsed and Refractory Multiple Myeloma-Review].嵌合抗原受体T细胞治疗复发难治性多发性骨髓瘤的新研究进展——综述
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1316-1320. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.053.
8
[Eukaryotic expression, protein purification and biological effects research of human CS1-Fc fusion protein].
Sheng Wu Gong Cheng Xue Bao. 2020 Jan 25;36(1):122-132. doi: 10.13345/j.cjb.190430.
9
CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.嵌合抗原受体T细胞及其他用于多发性骨髓瘤的细胞疗法：2018年更新
Am Soc Clin Oncol Educ Book. 2018 May 23;38:e6-e15. doi: 10.1200/EDBK_200889.
10
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.基于纳米抗体的抗 CD38 嵌合抗原受体 T 细胞的抗多发性骨髓瘤活性。
Mol Pharm. 2018 Oct 1;15(10):4577-4588. doi: 10.1021/acs.molpharmaceut.8b00584. Epub 2018 Sep 21.
引用本文的文献
1
[Mechanisms and prevention strategies of relapse and resistance after BCMA-CAR-T cell in multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):778-781. doi: 10.3760/cma.j.issn.0253-2727.2021.09.014.
本文引用的文献
1
Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.5-氮杂-2'-脱氧胞苷治疗可诱导NY-ESO-1表达并促进细胞毒性T淋巴细胞介导的肿瘤细胞杀伤。
PLoS One. 2015 Oct 8;10(10):e0139221. doi: 10.1371/journal.pone.0139221. eCollection 2015.
2
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.用于治疗多发性骨髓瘤的靶向CD19的嵌合抗原受体T细胞
N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.
3
Cancer gene therapy with T cell receptors and chimeric antigen receptors.利用T细胞受体和嵌合抗原受体进行癌症基因治疗。
Curr Opin Pharmacol. 2015 Oct;24:113-8. doi: 10.1016/j.coph.2015.08.006. Epub 2015 Sep 4.
4
[Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266].泊马度胺联合嵌合抗原受体T细胞（CAR-T）对多发性骨髓瘤细胞RPMI8226和U266的细胞毒性
Zhonghua Xue Ye Xue Za Zhi. 2015 Jun;36(6):497-500. doi: 10.3760/cma.j.issn.0253-2727.2015.06.011.
5
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.癌-睾丸抗原SLLP1是多发性骨髓瘤免疫治疗的一个有前景的靶点。
J Transl Med. 2015 Jun 20;13:197. doi: 10.1186/s12967-015-0562-5.
6
Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma.
Mol Immunol. 2015 Oct;67(2 Pt A):89-94. doi: 10.1016/j.molimm.2015.04.013. Epub 2015 May 8.
7
Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells.通过激活细胞外信号调节激酶1/2（ERK1/2）、蛋白激酶B（Akt）和核因子κB（NF-κB）使生存素过表达在多发性骨髓瘤细胞对长春新碱的耐药中起核心作用。
Leuk Res. 2015 Apr;39(4):445-52. doi: 10.1016/j.leukres.2015.01.016. Epub 2015 Feb 12.
8
MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.MDX-1097 诱导针对 κ 多发性骨髓瘤细胞的抗体依赖性细胞细胞毒性，其活性可被来那度胺增强。
Br J Haematol. 2015 May;169(3):333-43. doi: 10.1111/bjh.13298. Epub 2015 Feb 3.
9
DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.基于DNAM-1的嵌合抗原受体增强T细胞效应功能并在体内对黑色素瘤显示出疗效。
Cancer Immunol Immunother. 2015 Apr;64(4):409-18. doi: 10.1007/s00262-014-1648-2. Epub 2014 Dec 31.
10
Cell membrane associated free kappa light chains are found on a subset of tonsil and in vitro-derived plasmablasts.
Hum Immunol. 2014 Sep;75(9):986-90. doi: 10.1016/j.humimm.2014.08.196. Epub 2014 Aug 19.
Zotero 插件